Variant lymphoproliferative disorder of granular lymphocytes (LDGL) following Hodgkin lymphoma.
A 41-year-old Caucasian female was diagnosed with a CD3(+) CD4(+) CD8(+) variant of lymphoproliferative disorder of granular lymphocytes (LDGL) in the third year of remission following treatment of stage III-B Hodgkin lymphoma (HL). The patient was asymptomatic at diagnosis, without clinical evidence of immune disorder or recurrence of HL. Diagnosis was made incidentally, secondary to lymphocytosis discovered on a routine follow-up post HL therapy. Clonal chromosomal abnormalities were seen in 20% of peripheral blood lymphocytes with a karyotype 46, XX, t(2;6;2;11) (p13;q23;q24;q23). The breakpoint on 11q23 is distal to the MLL gene as shown by fluorescence in situ hybridization (FISH) analysis. To our knowledge, this is the first report of variant LDGL in association with HL treatment with documented clonal chromosomal abnormalities.
Jenkins
Brian Douglas
BD
The Van Elslander Cancer Center, St. John Hospital and Medical Center, Detroit, Michigan 48236, USA.
Snower
Daniel
D
Mohamed
Anwar
A
Al-Katib
Ayad
A
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001761:Bleomycin / Q000009:adverse effects* / Q000627:therapeutic use; D017252:CD3 Complex / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000473:pathology; D018414:CD8-Positive T-Lymphocytes / Q000473:pathology; D002869:Chromosome Aberrations; D020732:Cytogenetic Analysis; D003606:Dacarbazine / Q000009:adverse effects* / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006098:Granulocytes / Q000473:pathology*; D006689:Hodgkin Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008218:Lymphocytosis / Q000139:chemically induced / Q000473:pathology; D008232:Lymphoproliferative Disorders / Q000097:blood* / Q000139:chemically induced* / Q000235:genetics; D009367:Neoplasm Staging; D010641:Phenotype; D013601:T-Lymphocytes / Q000378:metabolism / Q000473:pathology*; D014747:Vinblastine / Q000009:adverse effects* / Q000627:therapeutic use
D017252:CD3 Complex; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin